MGB
MAZE

Mass General Brigham’s Maze Therapeutics MAZE Stock Holding History

Mass General Brigham’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.16M Hold
239,994
– – 1.98% 5
2026
Q1 		$7.16M Hold
239,994
– – 1.53% 5
2025
Q4 		$9.94M Buy
+239,994
New +$8.25M 1.23% 4

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Mass General Brigham's MAZE Position: Q2 2026 in Review

Mass General Brigham held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 239,994 shares worth $7.16M. The position accounts for 1.98% of the portfolio, ranked #5.

Mass General Brigham first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.94M in Q4 2025. 66 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Mass General Brigham held 239,994 shares of Maze Therapeutics worth $7.16M as of Q2 2026.
  • Mass General Brigham left its Maze Therapeutics share count unchanged in Q2 2026.
  • Maze Therapeutics made up 1.98% of Mass General Brigham's portfolio in Q2 2026, its #5 holding.
  • Mass General Brigham first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mass General Brigham's Maze Therapeutics position peaked at $9.94M in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Mass General Brigham's 13F filing for Q2 2026, filed 7 Aug 2026.